Fig. 2
From: Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Antigen-positive relapse mechanism. A: T Cell Quality: Patients receiving chemotherapy drugs prior to T cell collection lead to low-quality T cells, resulting in suboptimal CAR-T cell products. B: Co-Stimulatory Domain: CART cells with 4-1BB co-stimulatory molecules persist in the bloodstream for a prolonged period than CART cells that structurally contain a CD28 co-stimulatory molecule. C: Different T Cell Subsets: CAR-T cells constructed by CD8 + T cells have a stronger tumor-killing ability than CD4 + CAR-T cells